Treatment of diabetes
OwnerJohn Dupreinventor
Life of this patent
Estimating the term…
Abstract
A method is provided for treating insulin-requiring diabetes by a regimen includig adiugsration of insulin and glucagon-like insulinotropic peptide or a related peptide.
Claims14
A method of treating insulin-requiring diabetes in a mammal comprising administering to the mammal in a suitable regimen an effective amount of insulin and an effective amount of a peptide comprising a peptide selected from the group consisting of
- (a) glucagon-like peptide 1(7-37);
- (b) glucagon-like peptide 1(7-36)amide;
- and
- (c) an effective fragment or analogue of (a) or (b).
Use of a peptide comprising a peptide selected from the group consisting of
- (a) glucagon-like peptide 1(7-37);
- (b) glucagon-like peptide 1(7-36)amide;
- and
- (c) an effective fragment or analogue of (a) or (b) for the preparation of a medicament for use in the treatment of insulin-requiring diabetes in a suitable regimen which additionally comprises treatment with insulin.
Use of a peptide comprising a peptide selected from the group consisting of
- (a) glucagon-like peptide 1(7-37);
- (b) glucagon-like peptide 1(7-36)amide;
- and
- (c) an effective fragment or analogue of (a) or (b) for the preparation of a medicament which also includes insulin for treatment of insulin-requiring diabetes.
A pharmaceutical composition for the treatment of insulin-requiring diabetes comprising an effective amount of a peptide comprising a peptide selected from the group consisting of
- (a) glucagon-like peptide 1(7-37),
- (b) glucagon-like peptide 1(7-36)amide;
- and
- (c) an effective fragment or analogue of (a) or (b) and a pharmaceutically acceptable carrier.
A method of treating Type-I diabetes in a mammal comprising administering to the mammal an effective amount of a peptide comprising a peptide selected from the group consisting of
- (a) glucagon-like peptide 1(7-37);
- (b) glucagon-like peptide 1(7-36)amide;
- and
- (c) an effective fragment or analogue of (a) or (b).
Use of a peptide comprising a peptide selected from the group consisting of
- (a) glucagon-like peptide 1(7-37);
- (b) glucagon-like peptide 1(7-36)amide;
- and
- (c) an effective fragment or analogue of (a) or (b) for the preparation of a medicament for use in the treatment of Type I diabetes.
Dependencies are inferred from the claim text.